The analysis included a range of RCTs and observational studies, which provided valuable insights into the effects of SGLT2 inhibitors on major CVDs, such as myocardial infarction, myocardial ischemia, stroke, and cardiovascular death. The gene discussed is SLC5A2; the disease is stroke disorder.